Last update Dec. 29, 2020
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
スリンダク is Sulindac in Japanese.Is written in other languages:
スリンダク belongs to this group or family:
|Protein Binding||93 - 98||%|
|Tmax||3 - 5||hours|
|T½||7.8 (Metab: 16.4)||hours|
Write us at email@example.com
e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
It is a nonsteroidal anti-inflammatory drug which possesses both analgesic and antipyretic activities.
It is indicated for the relief of signs and symptoms related to osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute painful shoulder and acute gouty arthritis.
Administration orally twice a day.
At the time this last update was completed, we did not find published data regarding the excretion of this substance through breast milk.
Its high plasma protein binding make it very unlikely its excretion into breast milk in significant amount.
Until there is further published data on this drug in relation to breastfeeding, known safer alternatives may be preferable, especially during the neonatal period and in cases of prematurity.